« Back to Record
Pannus, P., Depickère, S., Kemlin, D., Houben, S., Neven, K. Y., Heyndrickx, L., Michiels, J., Willems, E., De Craeye, S., Francotte, A., Chaumont, F., Olislagers, V., Waegemans, A., Verbrugghe, M., Schmickler, M.-N., Van Gucht, S., Dierick, K., Marchant, A., Desombere, I., Ariën, K. K., & Goossens, M. M. (2022). Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial. PLOS global public health, 2(12), e0001308. doi:10.1371/journal.pgph.0001308
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/357920



